Drugs / 188Re-NM-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04674722 | Aug 2020 → May 2024 | breast cancer | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 188Re-NM-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674722 ↗ |
| Modality | Protein / enzyme biologic | “Anti-HER2 single domain antibody will be labeled with 99mTc and 188Re to prepare 99mTc-NM-02 and 188Re-NM-02, respectively.” NCT04674722 ↗ |